Diabetics now have a new option thanks to the breakthrough new medication AFREZZA®, an inhaled insulin now available by prescription.
The labeling for AFREZZA®, mandates spirometry testing (specifically FEV1) to rule out chronic lung disease prior to initiating therapy, six months after initiation and every year thereafter1.
MD Spiro offers a number of spirometer options and the expertise to easily integrate spirometry into your practice. From the non-reimbursable, PulmoLife at $195 to the full featured MicroLab at $2,295, Micro Direct has a spirometer designed to meet your needs.
American Thoracic Society (ATS) Coding Recommendations
To aid in the coding for spirometry testing, the ATS has determined the appropriate ICD-9 codes and CPT codes. The following table lists examples of how to record these diagnosis and billing codes:
|Spirometry prior to initiation of therapy||94010*||V72.85 + code for underlying condition (diabetes) as additional diagnosis|
|Spirometry after first 6 months of therapy||94010*||V58.83 + V58.67 + code for underlying condition (diabetes) as additional diagnosis|
|Annual spirometry testing||94010*||V58.83 + V58.67 + code for underlying condition (diabetes) as additional diagnosis|
* It may also be appropriate to append this code with the “-32” modifier indicating that the test is “mandated” by the FDA as part of the labeling restrictions for inhaled insulin.2
For additional information, call us today at 800-588-3381.
a All Current Procedural Terminology (CPT) 5-digit number codes, descriptions, number modifiers, instructions, guidelines and other material are Copyright © 2014 American Medical Association. All rights reserved.
1. This information is not a substitute for medical advice and does not provide a complete summary of AFREZZA® or any inhaled insulin product or address all considerations in making treatment decisions regarding their use. Always refer to the complete product information provided by the manufacturer.
2. Modifier minute: modifier 32. American Academy of Professional Coders website. http://news.aapc.com/index.php/2013/04/modifier-minute. Accessed December 22, 2014.
AFREZZA® is a registered trademark owned by MannKind Corporation.
Micro Direct, Inc./MD Spiro is not sponsored by nor has any affiliation with Sanofi, US, Inc., MannKind or the AFREZZA® trademark.